Clinical Studies
RestoreX clinical evidence
RestoreX carries the strongest device-specific evidence on this site, a randomized trial plus follow-up data, but it is still a population result, not a personal guarantee.
RestoreX is featured as the lead evidence-backed device because the supporting literature is more specific and structured than what is currently highlighted for vacuum therapy. The core source set includes a randomized controlled trial of 110 men with curvature of 30 degrees or more, followed by a non-randomized follow-up extension.
Stronger evidence supports clearer language, not a blank check. The trial's positive findings on curvature and length sit alongside real limitations: no head-to-head comparison against other traction devices, follow-up data that lose the control group, and individual response that still varies.
How the evidence rates outcome by outcome
Curvature improvement: strong
Primary trial endpoint with a follow-up durability signal. This is the outcome the evidence supports most directly.
Length recovery: strong
Reported in the primary trial and sustained in follow-up. Same source set, same population caveats.
Erectile function: moderate
Validated questionnaires, but a secondary outcome with a smaller effect size than the structural endpoints.
Durability beyond 12 months: limited
Follow-up data exist, but the post-trial extension is not randomized and the sample shrinks.
Head-to-head vs other active devices: emerging
There is no direct comparator trial in the current source set. RestoreX evidence does not transfer to all traction devices.
Trial start
Enrollment
- 110 men with Peyronie's disease and curvature of 30° or more.
- Single-centre randomized controlled study design.
- Inclusion focused on chronic, stable disease, not active-phase patients.
Months 0–3
Randomization & active protocol
- 3:1 allocation to RestoreX or control group.
- Daily device use of roughly 30 to 90 minutes.
- Three-month active phase before the primary outcome read-out.
End of trial
Outcome assessment
- Curvature, length, and erectile-function measures captured.
- Validated questionnaires used for secondary outcomes.
- Adverse events recorded across both arms.
Post-trial
Follow-up extension
- Non-randomized follow-up: control group no longer present.
- Mean device use settled at roughly 31 minutes per day.
- Adds durability context but is not the same evidence tier as the trial itself.
RestoreX has enough device-specific clinical weight to justify confident educational language for curvature and length, while still requiring visible limitations and measured personal expectations.